Patients and colleagues ask me often about the cost of GLP-1 medications when insurance does not cover them. Wegovy and Zepbound are both FDA approved for weight management. Many patients run into the same barrier: their insurance plan excludes the drug entirely. In those cases, people end up paying cash, and the list price can be thousands of dollars a month.

Novo Nordisk now offers a cash pay path that changes the math for some patients. Through NovoCare Pharmacy, every Wegovy dose strength drops to 499 dollars for a 28 day supply, shipped directly to the patient’s home. This applies only when a patient’s insurance won’t cover Wegovy at all; if a commercial plan does cover it, a separate savings offer can drop the copay as low as 0 to 25 dollars, but the 499 dollar flat price is reserved for patients paying entirely out of pocket. Medicare and Medicaid patients don’t qualify. Sources: Novo Nordisk press release, August 5, 2025 (prnewswire.com), and the NovoCare savings program website (novocare.com).

I had a patient not long ago who had already tried to fill Wegovy at a local pharmacy. The pharmacist told her the cash price was over 1,300 dollars. She could not afford that. Under this new program, she can request her prescription be sent to NovoCare Pharmacy and receive the medication for 499 dollars a month instead. Still expensive. For some patients it is the only feasible way to continue therapy when insurance refuses to cover it.

Eli Lilly runs a comparable program for Zepbound. Both LillyDirect and NovoCare are really good in my experience. The paperwork is less than most insurance companies require, and both platforms are quick to get medications out to patients. I like them equally and don’t have a preference. Self pay patients can get Zepbound for 500 dollars a month, a 28 day supply, dispensed through a mail order pharmacy under LillyDirect, Lilly’s patient access platform, and shipped to the patient. The same coverage rule applies: this is for patients whose insurance doesn’t cover the drug, and Medicare, Medicaid, and other government insurance don’t qualify. Source: LillyDirect program site and Eli Lilly press announcement, August 2025.

These programs are designed for a narrow group: patients with no coverage at all, facing list prices that are otherwise out of reach.

If you are a patient considering these programs, the next step is to talk with your prescribing clinician. Prescriptions have to be routed to the designated mail order pharmacies to qualify for the flat cash price. Taking the prescription to a local retail pharmacy and expecting the same deal won’t work.

As a physician, I see how frustrating the access issue has become. Some patients with coverage pay very little. Others pay nothing. Then the next patient on my schedule that same day has no coverage at all and faces a price higher than their mortgage. These new programs don’t solve every problem. For patients paying entirely out of pocket, they make a real difference. Whether 499 or 500 dollars a month is enough is a fair question. It beats a price higher than a mortgage payment, and for now, that’s the trade on the table.

Sources: Novo Nordisk press release August 5, 2025, NovoCare savings program (novocare.com), Eli Lilly press materials August 2025, LillyDirect (lillydirect.com).

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.